Search

Your search keyword '"Etzion, Ohad"' showing total 165 results
Start Over Author "Etzion, Ohad" Search Limiters Available in Library Collection
165 results on '"Etzion, Ohad"'

5. Dynamic Elevation of Aromatic Amino Acids in Hepatitis C Virus-Induced Cirrhosis After a Standard Meal

Author

Hill, Kareen L., primary, Haddad, James A., additional, Ali, Rabab O., additional, Zhang, Grace Y., additional, Quinn, Gabriella M., additional, Townsend, Elizabeth, additional, Everson, Gregory T., additional, Helmke, Steve M., additional, Bagheri, Mohammadhadi, additional, Schoenfeld, Megan, additional, Yang, Shanna, additional, Koh, Christopher, additional, Levy, Elliot B., additional, Kleiner, David E., additional, Sacks, David B., additional, Etzion, Ohad, additional, and Heller, Theo, additional

Published
2023
Full Text
View/download PDF

9. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria

Author

Yang, Alexander H., Han, Ma Ai Thanda, Samala, Niharika, Rizvi, Bisharah S., Marchalik, Rachel, Etzion, Ohad, Wright, Elizabeth C., Cao, Liang, Hakim, Frances T., Jones, Elizabeth, Kapuria, Devika, Hickstein, Dennis D., Fowler, Daniel, Kanakry, Jennifer A., Kanakry, Christopher G., Kleiner, David E., Koh, Christopher, Pavletic, Steven Z., and Heller, Theo

Published
2022
Full Text
View/download PDF

10. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study

Author

Etzion, Ohad, Dahari, Harel, Yardeni, David, Issachar, Assaf, Nevo-Shor, Anat, Cohen-Naftaly, Michal, Ashur, Yaffa, Uprichard, Susan L., Arbib, Orly Sneh, Munteanu, Daniela, Braun, Marius, Cotler, Scott J., Abufreha, Naim, Keren-Naus, Ayelet, Shemer-Avni, Yonat, Mor, Orna, Murad, Jayanah, Novack, Victor, and Shlomai, Amir

Published
2020
Full Text
View/download PDF

11. Circulating isomiRs May Be Superior Biomarkers Compared to Their Corresponding miRNAs: A Pilot Biomarker Study of Using isomiR-Ome to Detect Coronary Calcium-Based Cardiovascular Risk in Patients with NAFLD.

Author

Makarenkov, Nataly, Yoel, Uri, Haim, Yulia, Pincu, Yair, Bhandarkar, Nikhil S., Shalev, Aryeh, Shelef, Ilan, Liberty, Idit F., Ben-Arie, Gal, Yardeni, David, Rudich, Assaf, Etzion, Ohad, and Veksler-Lublinsky, Isana

Subjects
CORONARY artery calcification, NON-alcoholic fatty liver disease, MICRORNA, CARDIOVASCULAR diseases risk factors, BIOMARKERS
Abstract

Circulating miRNAs are increasingly being considered as biomarkers in various medical contexts, but the value of analyzing isomiRs (isoforms of canonical miRNA sequences) has not frequently been assessed. Here we hypothesize that an in-depth analysis of the full circulating miRNA landscape could identify specific isomiRs that are stronger biomarkers, compared to their corresponding miRNA, for identifying increased CV risk in patients with non-alcoholic fatty liver disease (NAFLD)—a clinical unmet need. Plasma miRNAs were sequenced with next-generation sequencing (NGS). Liver fat content was measured with magnetic-resonance spectrometry (MRS); CV risk was determined, beyond using traditional biomarkers, by a CT-based measurement of coronary artery calcium (CAC) score and the calculation of a CAC score-based CV-risk percentile (CAC-CV%). This pilot study included n = 13 patients, age > 45 years, with an MRS-measured liver fat content of ≥5% (wt/wt), and free of overt CVD. NGS identified 1103 miRNAs and 404,022 different isomiRs, of which 280 (25%) and 1418 (0.35%), respectively, passed an abundance threshold. Eighteen (sixteen/two) circulating miRNAs correlated positively/negatively, respectively, with CAC-CV%, nine of which also significantly discriminated between high/low CV risk through ROC-AUC analysis. IsomiR-ome analyses uncovered 67 isomiRs highly correlated (R ≥ 0.55) with CAC-CV%. Specific isomiRs of miRNAs 101-3p, 144-3p, 421, and 484 exhibited stronger associations with CAC-CV% compared to their corresponding miRNA. Additionally, while miRNAs 140-3p, 223-3p, 30e-5p, and 342-3p did not correlate with CAC-CV%, specific isomiRs with altered seed sequences exhibited a strong correlation with coronary atherosclerosis burden. Their predicted isomiRs-specific targets were uniquely enriched (compared to their canonical miRNA sequence) in CV Disease (CVD)-related pathways. Two of the isomiRs exhibited discriminative ROC-AUC, and another two showed a correlation with reverse cholesterol transport from cholesterol-loaded macrophages to ApoB-depleted plasma. In summary, we propose a pipeline for exploring circulating isomiR-ome as an approach to uncover novel and strong CVD biomarkers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. A Simple, Rapid, and Effective Heparinase Protocol to Enable Nucleic Acid Study from Frozen Heparinized Plasma.

Author

Afruza, Rownock, Minerva, Nicole, Lack, Justin B., Chakraborty, Moumita, Haddad, James A., Ali, Rabab O., Koh, Christopher, Levy, Elliot B., Etzion, Ohad, and Heller, Theo

Subjects
PLASMA products, NUCLEOTIDE sequencing, HEPARIN
Abstract

Cell-free RNAs (cfRNAs) are promising analytes as non-invasive biomarkers and have even greater potential if tied in with metabolomics. Plasma is an optimal source for cfRNAs but is often derived from a variety of anticoagulants. Plasma obtained in heparin is suitable for metabolomics but is difficult to utilize for qPCR-based downstream analysis. In the present study, we aimed to develop a simple, time-efficient, and cost-effective heparinase protocol, followed by library preparation and sequencing of human plasma cfRNAs drawn and stored in heparin at −80 °C for several years. Blood was collected in CPT™ sodium heparin tubes from patients with chronic HCV infection (NCT02400216) at the National Institutes of Health (NIH) Clinical Center. Plasma cfRNAs were treated with heparinase I and used for library preparation and next-generation sequencing (NGS). Heparinase treatment maintained RNA integrity and allowed for successful library preparation for all the study subjects even with 7 ng of cfRNAs as starting material. The classification report derived from Pavian R package v1.2.0 showed no artificial reads. The abundance of chordate over microbial reads suggests no addition of experimental error through heparinase I treatment. We report a novel and practical approach to heparinase treatment for human plasma collected and frozen in sodium heparin for several years. This is an effective demonstration of utilizing heparin plasma for NGS and downstream transcriptomic research, which could then be integrated with metabolomics from the same samples, maximizing efficiency and minimizing blood draws. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

Author

Razavi, Homie A, Buti, Maria, Terrault, Norah A, Zeuzem, Stefan, Yurdaydin, Cihan, Tanaka, Junko, Aghemo, Alessio, Akarca, Ulus S, Al Masri, Nasser M, Alalwan, Abduljaleel M, Aleman, Soo, Alghamdi, Abdullah S, Alghamdi, Saad, Al-Hamoudi, Waleed K, Aljumah, Abdulrahman A, Altraif, Ibrahim H, Asselah, Tarik, Ben-Ari, Ziv, Berg, Thomas, Biondi, Mia J, Blach, Sarah, Braga, Wornei S M, Brandão-Mello, Carlos E, Brunetto, Maurizia R, Cabezas, Joaquin, Cheinquer, Hugo, Chen, Pei-Jer, Cheon, Myeong-Eun, Chuang, Wan-Long, Coffin, Carla S, Coppola, Nicola, Craxi, Antonio, Crespo, Javier, De Ledinghen, Victor, Duberg, Ann-Sofi, Etzion, Ohad, Ferraz, Maria Lucia G, Ferreira, Paulo R A, Forns, Xavier, Foster, Graham R, Gaeta, Giovanni B, Gamkrelidze, Ivane, García-Samaniego, Javier, Gheorghe, Liliana S, Gholam, Pierre M, Gish, Robert G, Glenn, Jeffrey, Hercun, Julian, Hsu, Yao-Chun, Hu, Ching-Chih, Huang, Jee-Fu, Janjua, Naveed, Jia, Jidong, Kåberg, Martin, Kaita, Kelly D E, Kamal, Habiba, Kao, Jia-Horng, Kondili, Loreta A, Lagging, Martin, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Mei-Hsuan, Lim, Young-Suk, Marotta, Paul J, Navas, Maria-Cristina, Naveira, Marcelo C M, Orrego, Mauricio, Osiowy, Carla, Pan, Calvin Q, Pessoa, Mário G, Raimondo, Giovanni, Ramji, Alnoor, Razavi-Shearer, Devin M, Razavi-Shearer, Kathryn, Ríos-Hincapié, Cielo Y, Rodríguez, Manuel, Rosenberg, William M C, Roulot, Dominique M, Ryder, Stephen D, Safadi, Rifaat, Sanai, Faisal M, Santantonio, Teresa A, Sarrazin, Christoph, Shouval, Daniel, Tacke, Frank, Tergast, Tammo L, Villalobos-Salcedo, Juan Miguel, Voeller, Alexis S, Yang, Hwai-I, Yu, Ming-Lung, Zuckerman, Eli, Razavi, Homie A, Buti, Maria, Terrault, Norah A, Zeuzem, Stefan, Yurdaydin, Cihan, Tanaka, Junko, Aghemo, Alessio, Akarca, Ulus S, Al Masri, Nasser M, Alalwan, Abduljaleel M, Aleman, Soo, Alghamdi, Abdullah S, Alghamdi, Saad, Al-Hamoudi, Waleed K, Aljumah, Abdulrahman A, Altraif, Ibrahim H, Asselah, Tarik, Ben-Ari, Ziv, Berg, Thomas, Biondi, Mia J, Blach, Sarah, Braga, Wornei S M, Brandão-Mello, Carlos E, Brunetto, Maurizia R, Cabezas, Joaquin, Cheinquer, Hugo, Chen, Pei-Jer, Cheon, Myeong-Eun, Chuang, Wan-Long, Coffin, Carla S, Coppola, Nicola, Craxi, Antonio, Crespo, Javier, De Ledinghen, Victor, Duberg, Ann-Sofi, Etzion, Ohad, Ferraz, Maria Lucia G, Ferreira, Paulo R A, Forns, Xavier, Foster, Graham R, Gaeta, Giovanni B, Gamkrelidze, Ivane, García-Samaniego, Javier, Gheorghe, Liliana S, Gholam, Pierre M, Gish, Robert G, Glenn, Jeffrey, Hercun, Julian, Hsu, Yao-Chun, Hu, Ching-Chih, Huang, Jee-Fu, Janjua, Naveed, Jia, Jidong, Kåberg, Martin, Kaita, Kelly D E, Kamal, Habiba, Kao, Jia-Horng, Kondili, Loreta A, Lagging, Martin, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Mei-Hsuan, Lim, Young-Suk, Marotta, Paul J, Navas, Maria-Cristina, Naveira, Marcelo C M, Orrego, Mauricio, Osiowy, Carla, Pan, Calvin Q, Pessoa, Mário G, Raimondo, Giovanni, Ramji, Alnoor, Razavi-Shearer, Devin M, Razavi-Shearer, Kathryn, Ríos-Hincapié, Cielo Y, Rodríguez, Manuel, Rosenberg, William M C, Roulot, Dominique M, Ryder, Stephen D, Safadi, Rifaat, Sanai, Faisal M, Santantonio, Teresa A, Sarrazin, Christoph, Shouval, Daniel, Tacke, Frank, Tergast, Tammo L, Villalobos-Salcedo, Juan Miguel, Voeller, Alexis S, Yang, Hwai-I, Yu, Ming-Lung, and Zuckerman, Eli

Abstract

Hepatitis D virus (HDV) infection occurs as a coinfection with hepatitis B and increases the risk of hepatocellular carcinoma, decompensated cirrhosis, and mortality compared to hepatitis B virus (HBV) monoinfection. Reliable estimates of the prevalence of HDV infection and disease burden are essential to formulate strategies to find coinfected individuals more effectively and efficiently. The global prevalence of HBV infections was estimated to be 262,240,000 in 2021. Only 1,994,000 of the HBV infections were newly diagnosed in 2021, with more than half of the new diagnoses made in China. Our initial estimates indicated a much lower prevalence of HDV antibody (anti-HDV) and HDV RNA positivity than previously reported in published studies. Accurate estimates of HDV prevalence are needed. The most effective method to generate estimates of the prevalence of anti-HDV and HDV RNA positivity and to find undiagnosed individuals at the national level is to implement double reflex testing. This requires anti-HDV testing of all hepatitis B surface antigen-positive individuals and HDV RNA testing of all anti-HDV-positive individuals. This strategy is manageable for healthcare systems since the number of newly diagnosed HBV cases is low. At the global level, a comprehensive HDV screening strategy would require only 1,994,000 HDV antibody tests and less than 89,000 HDV PCR tests. Double reflex testing is the preferred strategy in countries with a low prevalence of HBV and those with a high prevalence of both HBV and HDV. For example, in the European Union and North America only 35,000 and 22,000 cases, respectively, will require anti-HDV testing annually.

Published
2023
Full Text
View/download PDF

19. Postprandial Plasma Lipidomics Reveal Specific Alteration of Hepatic-derived Diacylglycerols in Nonalcoholic Fatty Liver Disease

Author

Velenosi, Thomas J., primary, Ben-Yakov, Gil, additional, Podszun, Maren C., additional, Hercun, Julian, additional, Etzion, Ohad, additional, Yang, Shanna, additional, Nadal, Cathy, additional, Haynes-Williams, Vanessa, additional, Huang, Wen-Chun A., additional, González-Hódar, Lila, additional, Brychta, Robert J., additional, Takahashi, Shogo, additional, Akkaraju, Vikas, additional, Krausz, Kristopher W., additional, Walter, Mary, additional, Cai, Hongyi, additional, Walter, Peter J., additional, Muniyappa, Ranganath, additional, Chen, Kong Y., additional, Gonzalez, Frank J., additional, and Rotman, Yaron, additional

Published
2022
Full Text
View/download PDF

20. Chronic hepatitis C:Diagnosis and treatment made easy

Author

Abu-Freha, Naim, Mathew Jacob, Binil, Elhoashla, Ali, Afawi, Zaid, Abu-Hammad, Talab, Elsana, Foad, Paz, Sergey, Etzion, Ohad, Abu-Freha, Naim, Mathew Jacob, Binil, Elhoashla, Ali, Afawi, Zaid, Abu-Hammad, Talab, Elsana, Foad, Paz, Sergey, and Etzion, Ohad

Abstract

Background: Hepatitis C Virus (HCV) is a common cause of chronic liver disease and its ensuing complications. In the last years, there has been a revolution of the treatment for patients with HCV regarding efficacy, simplicity, safety and duration of treatment. The role of the family physician is vital in all steps of care: screening, diagnosis, linkage to treatment, treatment and follow-up. Objectives: This review aims to summarise the family physician and the important updated recommendations for diagnosis and treatment of patients with chronic HCV. Methods: The updated recommendations were reviewed and summarised in a short and simple review. Results: Patients with any risk factor for HCV should first be screened for HCV antibodies. In the case of positive antibodies, reflex testing for RNA polymerase chain reaction (PCR) should be done without waiting for genotype. For patients with positive PCR, fibrosis assessment should be conducted using laboratory panels (Fibrosis-4 index (FIB-4) or aspartate aminotransferase to platelet ratio index (APRI)); if advanced fibrosis is suspected, additional non-invasive fibrosis assessment is needed, such as fibrotest or liver elastography. Naïve non-cirrhotic or compensated cirrhosis (Child-Pugh-Score A) could be treated with pangenotypic drugs, Glecaprevir/pibrentasvir (Maviret) for eight weeks, or Sofosbuvir/velpatasvir (Epclusa) for 12 weeks. Conclusion: Patients without advanced fibrosis and comorbidities can be treated by the educated family physician. However, patients with comorbidities, cirrhosis or coinfection (HIV, Hepatitis B Virus (HBV)) should be referred to the liver clinic. In case of screening patients with risk factors or likelihood of dormant HCV, health organisations should provide the appropriate resources, logistics, finances and workforce.

Published
2022

22. Abnormal liver tests are not sufficient for diagnosis of hepatic graft‐versus‐host disease in critically ill patients

Author

Yang, Alexander H., primary, Han, Mai Ai Thanda, additional, Samala, Niharika, additional, Rizvi, Bisharah S., additional, Marchalik, Rachel, additional, Etzion, Ohad, additional, Wright, Elizabeth C., additional, Patel, Ruchi, additional, Khan, Vinshi, additional, Kapuria, Devika, additional, Samala Venkat, Vikramaditya, additional, Kleiner, David E., additional, Koh, Christopher, additional, Kanakry, Jennifer A., additional, Kanakry, Christopher G., additional, Pavletic, Steven, additional, Williams, Kirsten M., additional, and Heller, Theo, additional

Published
2022
Full Text
View/download PDF

28. Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum.

Author

Kushner, Tatyana, Nyabanga, Custon T, Cotler, Scott J, Etzion, Ohad, and Dahari, Harel

Abstract

Treating hepatitis C virus (HCV) in pregnancy would address HCV during prenatal care and potentially reduce the risk of vertical transmission. Response-guided therapy could provide a means to individualize and the reduce duration of HCV treatment during pregnancy. Data from a 27-year-old woman indicated that, pretreatment, HCV was stable and that it dropped in a biphasic manner during sofosbuvir/velpatasvir therapy, reaching target not detected at time of delivery—16 days post–initiation of therapy. Mathematical modeling of measured HCV at days 0, 7, and 14 predicted that cure could have been achieved after 7 weeks of sofosbuvir/velpatasvir, reducing the duration of therapy by 5 weeks. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Fr426 LIVER ABNORMALITIES IN TURNER'S SYNDROME

Author

Rai, Anjali, primary, Etzion, Ohad, additional, Han, Ma Ai Thanda, additional, Patel, Ruchi, additional, Ko, Christopher, additional, Kleiner, David, additional, Mousa, Omar Y., additional, Loomba, Rohit, additional, Bakalov, Vladimir, additional, Takyar, Varun, additional, and Heller, Theo, additional

Published
2021
Full Text
View/download PDF

34. Adherence to Anti-Viral Treatment for Chronic Hepatitis B

Author

Abu-Freha, Naim, primary, Abu Tailakh, Muhammad, additional, Fich, Alexander, additional, Abu Bader, Nasreen, additional, Shemer-Avni, Yonat, additional, Alsana, Farhan, additional, Gasper, Nava, additional, Abu-Kaf, Heba, additional, and Etzion, Ohad, additional

Published
2020
Full Text
View/download PDF

36. 378 ELUCIDATING THE MECHANISM OF CIRRHOSIS-ASSOCIATED SARCOPENIA BY INTERROGATING THE GUT-LIVER AXIS

Author

Ali, Rabab O., primary, Quinn, Gabriella M., additional, Hill, Kareen, additional, Haddad, James, additional, Zhang, Grace, additional, Han, Jungmin, additional, Periwal, Vipul, additional, Koh, Christopher, additional, Levy, Elliot, additional, Kleiner, David, additional, Etzion, Ohad, additional, Sacks, David B., additional, and Heller, Theo, additional

Published
2020
Full Text
View/download PDF

37. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Author

Yurdaydin, Cihan, Abbas, Zaigham, Buti, Maria, Cornberg, Markus, Esteban, Rafael, Etzion, Ohad, Gane, Edward J., Gish, Robert G., Glenn, Jeffrey S., Hamid, Saeed, Heller, Theo, Koh, Christopher, Lampertico, Pietro, Lurie, Yoav, Manns, Michael, Parana, Raymundo, Rizzetto, Mario, Urban, Stephan, Wedemeyer, Heiner, Wranke, Anika, Pinheiro Borzacov, Lourdes M., Lobato, Cirley Maria de Oliveira, Hamid, Saeed Sadiq, Ceausu, Emanoil, Dalekos, George N., Turcanu, Adela, Niro, Grazia Anna, Lubna, Farheen, Abbas, Minaam, Ingiliz, Patrick, Ferenci, Péter, Vanwolleghem, Thomas, Hayden, Tonya, Dashdorj, Naranjargal R., Motoc, Adriana, Hardtke, Svenja, Hepatitis Delta International Network (HDIN), Yurdaydın, Cihan, Abbas, Zaigham, Buti, Maria, Cornberg, Markus, Esteban, Rafael, Etzion, Ohad, Ganes, Edward J., Gish, Robert G., Glenn, Jeffrey S., Hamids, Saeed, Heller, Theo, Koh, Christopher, Lampertico, Pietro, Lurie, Yoav, Manns, Michael, Parana, Raymundo, Rizzetto, Mario, Urban, Stephan, Wedemeyer, Heiner, Wranke, A., Borzacov, Pinheiro L. M., Lobato, C., Hamid, S., Ceausu, E., Dalekos, G. N., Turcanu, A., Niro, G. A., Lubna, F., Abbas, M., Ingiliz, P., Ferenci, P., Vanwolleghem, T., Hayden, T., Dashdorj, N., Motoc, A., Hardtke, S., School of Medicine, and Department of Internal Medicine

Subjects
0301 basic medicine, Medicine, Gastroenterology and hepatology, Hepatitis D, Chronic, Polymers, Pyridines, viruses, Medizin, Virus, 03 medical and health sciences, Lipopeptides, 0302 clinical medicine, Chronic hepatitis, Piperidines, Nucleic Acids, Clinical endpoint, Humans, Clinical Trials as Topic, Hepatitis B Surface Antigens, Hepatology, business.industry, Surrogate endpoint, virus diseases, biochemical phenomena, metabolism, and nutrition, medicine.disease, Hepatitis D, Treatment efficacy, Clinical trial, 030104 developmental biology, Treatment Outcome, Liver, Treatment endpoints, Surrogate marker, New treatment approaches, Immunology, RNA, Viral, 030211 gastroenterology & hepatology, business, Viral hepatitis, Biomarkers
Abstract

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials., NA

Published
2018

39. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy

Author

Yurdaydın, Cihan, Abbas, Zaigham; Buti, Maria; Cornberg, Markus; Esteban, Rafael; Etzion, Ohad; Ganes, Edward J.; Gish, Robert G.; Glenn, Jeffrey S.; Hamids, Saeed; Heller, Theo; Koh, Christopher; Lampertico, Pietro; Lurie, Yoav; Manns, Michael; Parana, Raymundo; Rizzetto, Mario; Urban, Stephan; Wedemeyer, Heiner; Wranke, A.; Borzacov, Pinheiro L. M.; Lobato, C.; Hamid, S.; Ceausu, E.; Dalekos, G. N.; Turcanu, A.; Niro, G. A.; Lubna, F.; Abbas, M.; Ingiliz, P.; Ferenci, P.; Vanwolleghem, T.; Hayden, T.; Dashdorj, N.; Motoc, A.; Hardtke, S., School of Medicine, Department of Internal Medicine, Yurdaydın, Cihan, Abbas, Zaigham; Buti, Maria; Cornberg, Markus; Esteban, Rafael; Etzion, Ohad; Ganes, Edward J.; Gish, Robert G.; Glenn, Jeffrey S.; Hamids, Saeed; Heller, Theo; Koh, Christopher; Lampertico, Pietro; Lurie, Yoav; Manns, Michael; Parana, Raymundo; Rizzetto, Mario; Urban, Stephan; Wedemeyer, Heiner; Wranke, A.; Borzacov, Pinheiro L. M.; Lobato, C.; Hamid, S.; Ceausu, E.; Dalekos, G. N.; Turcanu, A.; Niro, G. A.; Lubna, F.; Abbas, M.; Ingiliz, P.; Ferenci, P.; Vanwolleghem, T.; Hayden, T.; Dashdorj, N.; Motoc, A.; Hardtke, S., School of Medicine, and Department of Internal Medicine

Abstract

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials., NA

Published
2019

40. 409 – Integration of the Fecal Metatranscriptome, Portal Vein Metabolome, and Liver Transcriptome in Order to Gain Insight Into the Microbiome's Importance in Hcv-Induced Liver Injury

Author

Quinn, Gabriella, primary, Ali, Rabab, additional, Hill, Kareen, additional, Zhang, Grace, additional, Townsend, Elizabeth, additional, Etzion, Ohad, additional, Koh, Christopher, additional, Levy, Elliot, additional, Kleiner, David, additional, and Heller, Theo, additional

Published
2019
Full Text
View/download PDF

43. Sa1528 – Emerging Role of Hypotaurine and Taurine Amino Acids in Chronic Hepatitis C Associated Chronic Liver Disease Before and After Hcv Clearance

Author

Ali, Rabab, primary, Quinn, Gabriella, additional, Hill, Kareen, additional, Zhang, Grace, additional, Townsend, Elizabeth, additional, Koh, Christopher, additional, Rampertaap, Shakuntala, additional, Rosenzweig, Sergio, additional, Levy, Elliot, additional, Kleiner, David, additional, Etzion, Ohad, additional, and Heller, Theo, additional

Published
2019
Full Text
View/download PDF

45. Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension

Author

Etzion, Ohad, primary, Takyar, Varun, additional, Novack, Victor, additional, Gharib, Ahmed M., additional, Canales, Raissa, additional, Adebogun, Akeem, additional, Matsumoto, Eric, additional, Eccleston, Jason L., additional, Kleiner, David E., additional, Rosenzweig, Sergio D., additional, Gunay‐Aygun, Meral, additional, Uzel, Gulbu, additional, Fuss, Ivan, additional, Childs, Richard, additional, Holland, Steven M., additional, Levy, Elliot B., additional, Liang, T. Jake, additional, Heller, Theo, additional, and Koh, Christopher, additional

Published
2018
Full Text
View/download PDF

47. Mo1491 - Fibroscan in Sickle Cell Liver Disease-Could we Strike while the Liver is Hard?

Author

Ben-Yakov, Gil S., primary, Alao, Hawwa, additional, Surana, Pallavi, additional, Kapuria, Devika, additional, Etzion, Ohad, additional, Hsieh, Matthew M., additional, Tisdale, John F., additional, Courtney, Fitzhugh D., additional, Kleiner, David, additional, Levy, Elliot B., additional, Richard, Chang F., additional, Rivera, Elenita F., additional, Huang, Amy, additional, Koh, Christopher, additional, and Heller, Theo, additional

Published
2018
Full Text
View/download PDF

48. Mo1416 - Changes in Portal and Peripheral Cytokines Following Hepatitic C Virus Clearance; A Window Into the Link Between Liver Disease and Host Immunity

Author

Ali, Rabab, primary, Scheuing, Lisa, additional, Quinn, Gabriella, additional, Hill, Kareen, additional, Zhang, Grace, additional, Townsend, Elizabeth, additional, Koh, Christopher, additional, Levy, Elliot B., additional, Kleiner, David, additional, Etzion, Ohad, additional, and Heller, Theo, additional

Published
2018
Full Text
View/download PDF

49. Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection—A randomized controlled trial

Author

Munteanu, Daniela, primary, Etzion, Ohad, additional, Ben-Yakov, Gil, additional, Halperin, Daniel, additional, Eidelman, Leslie, additional, Schwartz, Doron, additional, Novack, Victor, additional, Abufreha, Naim, additional, Krugliak, Pavel, additional, Rozenthal, Alexander, additional, Gaspar, Nava, additional, Moshkalo, Alexander, additional, Dizingof, Vitaly, additional, and Fich, Alexander, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results